|
Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. |
|
|
Consulting or Advisory Role - Pfizer |
|
|
Research Funding - Amgen (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer |
|
|
Honoraria - ADC Therapeutics; amgen; Gilead Sciences; Sigma-Tau |
Research Funding - Sigma-Tau (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date |
|
|
Honoraria - Amgen; Pfizer |
Research Funding - Amgen; Amgen (Inst); Pfizer; Pfizer (Inst) |
|
|
Consulting or Advisory Role - AMGEN; ARIAD; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
|
|
Honoraria - Celgene; Gilead Sciences; Janssen; Pfizer; Pharmacyclics; ProNAi; Regeneron |
Consulting or Advisory Role - Amgen; Celgene; CLL Global Research Foundation |
Research Funding - Acerta Pharma; Gilead Sciences; Regeneron |
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Regeneron |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Research Funding - Pfizer |
|
|
Research Funding - Amgen; Astex Pharmaceuticals; Bristol-Myers Squibb; Novartis; Pfizer |